Home > News > CytImmune to wait for drug’s approval
May 19th, 2006
CytImmune to wait for drug’s approval
Abstract:
Perhaps Tamarkin is also patient because, if Aurimune is approved, its market size "would be extraordinarily significant, billions of dollars," he said. In the United States alone, there are close to 1 million new patients a year, he said.
Aurimune is a nanotech product and the FDA is adjusting its drug approval process for such products. Aurimune uses CytImmune’s patented method of attaching drugs to a molecule of colloidal gold to carry the drugs safely — in animals, so far — through the bloodstream.
Source:
gazette.net
Related Links |
Related News Press |
Preparing for Nano
Disruptive by Design: Nano Now February 1st, 2019
How nanoscience will improve our health and lives in the coming years: Targeted medicine deliveries and increased energy efficiency are just two of many ways October 26th, 2016
Searching for a nanotech self-organizing principle May 1st, 2016
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Profiles
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||